Microbial colonization of medical devices and novel preventive strategies

Recent Patents on Drug Delivery and Formulation

Volumn 4, Issue 2, 2010, Pages 153-173

  Shunmugaperumal, Tamilvanan ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Catheters; Colonization; Implants; Liposomes; Medical devices; Microbial biofilm; Quorum sensing

Indexed keywords

2,3,3,4 METHYLTETRAHYDROXYTETRAHYDROFURAN; ALCOHOL; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; BIOMATERIAL; BONE CEMENT; CEFOPERAZONE; CIPROFLOXACIN; DNA VACCINE; DUOCID; EDETATE DISODIUM; ELLAGITANNIN; FURANONE DERIVATIVE; GENTAMICIN; LIPOSOME; LYSOSTAPHIN; MINOCYCLINE; N ACYLHOMOSERINE LACTONE; PATULIN; PENICILLIN G; POLYGLACTIN; POLYLACTIC ACID; POLYPEPTIDE ANTIBIOTIC AGENT; RNA III INHIBITING PEPTIDE; SERRAWETTIN W2; SULPERAZONE; TAUROLIDINE; TETRAHYDROFURAN DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIOPHAGE; BIOFILM; CATHETER; CATHETER INFECTION; CHEMICAL INTERACTION; COMPOSITE MATERIAL; DRUG DELIVERY SYSTEM; DRUG ISOLATION; DRUG POTENTIATION; DRUG SYNTHESIS; ELECTROCHEMISTRY; ELECTROSTIMULATION; FOREIGN BODY REACTION; HOST PATHOGEN INTERACTION; HUMAN; HYDROGEL; INSTRUMENT STERILIZATION; IRON METABOLISM; MACROPHAGE ACTIVATION; MATERIAL COATING; MEDICAL INSTRUMENTATION; MICROBIAL COLONIZATION; MICROBIAL CONTAMINATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; QUORUM SENSING; SIGNAL TRANSDUCTION; ULTRASOUND; VACCINATION;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOFILMS; DRUG CARRIERS; EQUIPMENT AND SUPPLIES; HUMANS; LIPIDS; PATENTS AS TOPIC; POLYMERS; PROSTHESES AND IMPLANTS; PROSTHESIS-RELATED INFECTIONS;

EID: 77954060519     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221110791185006     Document Type: Article

References (257)

1. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
2. Watnick P, Kolter R. Biofilm, city of microbes. J Bacteriol 2000; 182: 2675-9.
3. Liliana, A., Jan, W., Robert, W.W., Micheal, S. Drug eluting medical devices having porous layers. US2008070842 (2008).
4. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008; 20: 86-100.
5. Malcolm RK, McCullagh SD, Woolfson AD, Gorman SP, Jones DS, Cuddy J. Controlled release of a model antibacterial drug from a novel self-lubricating silicone biomaterial. J Control Release 2004; 97: 313-20.
6. Jones DS, Garvin CP, Dowling D, Donnelly K, Gorman SP. Examination of surface properties and in vitro biological performance of amorphous diamond-like carbon-coated polyurethane. J Biomed Mater Res Part B: Appl Biomater 2006; 78B: 230-6.
7. Matthew A, Myer B, Rushton N. in vitro and in vivo Investigations into the biocompatibility of diamond-like carbon (DLC) coatings for orthopedic applications. J Biomed Mater Res 2001; 58: 319-28.
8. Jones MI, McColl R, Grant DM, Parker KG, Parker TL. Protein adsorption and platelet attachment and activation, on TiN, TiC, and DLC coatings on titanium for cardiovascular applications. J Biomed Mater Res 2000; 52: 413-21.
9. Dowling DP, Donnelly K, O'Brien TP. Application of diamond like carbon films as hermetic coatings on optical fibres. Diam Relat Mater 1996; 5: 492-5.
10. Duran LW. Preventing medical device related infections. Med Device Technol 2000; 11: 14-7.
11. Dwyer A. Surface-treated catheters-a review. Semin Dial 2008; 21(6): 542-6.
12. Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun 2005; 73(10): 6350-62.
13. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2(9): 695-703.
14. Cachia PJ, Hodges RS. Synthetic peptide vaccine and antibody therapeutic development: Prevention and treatment of Pseudomonas aeruginosa. Biopolymers 2003; 71(2): 141-68.
15. Otto M. Quorum-sensing control in Staphylococci-A target for antimicrobial drug therapy? FEMS Microbiol Lett 2004; 241: 135-41.
16. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007; 117(4): 877-88.
17. Boles BR, Thoendel M, Singh PK. Rhamnolipids mediate detachment of Pseudomonas aeruginosa from biofilms. Mol Microbiol 2005; 57: 1210-23.
18. Zulianello, L., Meda, P. Rhamnose antagonists and use thereof. WO2009040726 (2009).
19. Reisner A, Høiby N, Tolker-Nielsen T, Molin S. Microbial pathogenesis and biofilm development. Cont Microbiol 2005; 12: 114-31.
20. Fux CA, Stoodley P, Hall-Stoodley L, Costerton JW. Bacterial biofilms: A diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 2003; 1(4): 667-83.
21. Foster TJ. Immune evasion by Staphylococci. Nat Rev Microbiol 2005; 3: 948-58.
22. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13(1): 34-40.
23. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 2002; 292: 107-13.
24. Bjarnsholt T, Givskov M. Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Philos Trans R Soc Lond B Biol Sci 2007; 362(1483): 1213-22.
25. Høiby N. Understanding bacterial biofilms in patients with cystic fibrosis: Current and innovative approaches to potential therapies. J Cyst Fibros 2002; 1(4): 249-54.
26. Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol 2008; 52(1): 13-22.
27. Bakaletz LO. Bacterial biofilms in otitis media: Evidence and relevance. Pediatr Infect Dis J 2007; 10 (Suppl): S17-S19.
28. Post JC, Hiller NL, Nistico L, Stoodley P, Ehrlich GD. The role of biofilms in otolaryngologic infections: Update 2007. Curr Opin Otolaryngol Head Neck Surg 2007; 15(5): 347-51.
29. Offenbacher S, Barros SP, Singer RE, Moss K, Williams RC, Beck JD. Periodontal disease at the biofilm-gingival interface. J Periodontol 2007; 78(10): 1911-25.
30. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique; A new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 1988; 12: 185-9.
31. Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF. Barker J, Allon M. Management of hemodialysis catheter-related bacteraemia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61: 1136-42.
32. Jones GR, Konsler GK, Dunaway RP. Urokinase in the treatment of bacteraemia and candidaemia in patients with right atrial catheters. Am J Infect Control 1996; 24: 160-6.
33. La Quaglia MP, Caldwell C, Lucas A, Corbally M, Heller G, Steinherz L, Brown AE, Groeger J, Exelby PR. A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. J Pediatr Surg 1994; 29: 742-5.
34. Capdevila JA, Gavalda J, Fortea J, López P, Martin MT, Gomis X, Pahissa A. Lack of antimicrobial activity of sodium heparin for treating experimental catheter related infection due to Staphylococcus aureus using the antibiotic-lock technique. Clin Microbiol Infect 2001; 7: 206-12.
35. Sieradzki K, Roberts RB, Serur D, Hargrave J, Tomasz A. Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy. J Clin Microbiol 1999; 37: 39-44.
36. Traub WH, Leonhard B, Bauer D. Taurolidine: In vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. Chemotherapy 1993; 39: 322-30.
37. Jones DS, Gorman SP, McCafferty DF, Woolfson AD. The effects of three non-antibiotic, antimicrobial agents on the surface hydrophobicity of certain microorganisms evaluated by different methods. J Appl Bacteriol 1991; 71: 218-27.
38. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, DeGirolami P, Farris MG, Wennersten CB, et al. Activities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2000; 44: 1720-24.
39. Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, et al. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46: 1674-79.
40. Bradshaw JH, Puntis JW. Taurolidine and catheter-related bloodstream infection: a systemic review of the literature. J Pediatr Gastroenterol Nutr 2008; 47(2): 179-86.
41. Johnston DA, Phillips G, Perry M, McAlpine H, Richards J, Pennington CR. Taurolin for the prevention of parenteral nutrition related infection: Antimicrobial activity and long-term use. Clin Nutr 1993; 12: 365-8.
42. Dannenberg C, Bierbach U, Rothe A, Beer J, Körholz D. Ethanollock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol 2003; 25: 616-21.
43. Metcalf SCL, Chambers ST, Pithie AD. Use of ethanol locks to prevent recurrent central line sepsis. J Infect 2004; 49: 20-2.
44. Raad I, Buzaid A, Rhyne J, Hachem R, Darouiche R, Safar H, et al. Minocycline and ethylenediaminetetra-acetate for the prevention of recurrent vascular catheter infections. Clin Infect Dis 1997; 25: 149-51.
45. Root JL, McIntyre OR, Jacobs NJ, Daghlian CP. Inhibitory effect of disodium EDTA upon the growth of Staphylococcus epidermidis in vitro: Relation to infection prophylaxis of Hickman catheters. Antimicrob Agents Chemother 1988; 32: 1627-31.
46. Turakbia MH, Cooksey KE, Characklis WG. Influence of a calcium-specific chelant on biofilm emoval. Appl Environ Microbiol 1983; 46: 1236-8.
47. Percival SL, Kite P, Eastwood K, Murga R, Carr J, Arduino MJ, et al. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infect Control Hosp Epidemiol 2005; 26: 515-9.
48. Kite P, Eastwood K, Sugden S, Percival SL. Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol 2004; 42: 3073-6.
49. Raad I, Chatzinikolaou I, Chaiban G, Hanna H, Hachem R, Dvorak T, Cook G, Costerton W. in vitro and ex vivo Activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob Agents Chemother 2003; 47: 3580-5.
50. Stephen, R.A. Method of enhancing catheter patency using a citrate salt catheter lock solution. US6958049 (2005).
51. Stephen, R.A. A catheter lock solution including a photo-oxidant. EP1284780 (2008).
52. Steczko J, Ash SR, Nivens DE, Brewer L, Winger RK. Microbial inactivation of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens). Nephrol Dial Transplant 2009; 24(6): 1937-45.
53. Ash, S., Steczko, J., Swanson, G.L. A catheter locks solution comprising citrate and a paraben. WO2006086250 and US200600397 (2006).
54. von Eiff C, Kokai-Kun JF, Becker K, Peters G. in vitro Activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob Agents Chemother 2003; 47: 3613-5.
55. Patron RL, Climo MW, Goldstein BP, Archer GL. Lysostaphin treatment of experimental aortic value endocarditis caused by a Staphylococcus aureus isolate with reduce susceptibility to vancomycin. Antimicrob Agents Chemother 1999; 43: 1754-55.
56. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 2003; 47: 3407-14.
57. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552-5.
58. Cohen, N.A., O'Malley, B.W.J., Chiu, A.G., Palmer, J.N., Steiger, J.D. Biofilm prevention using lactoferrin. WO2009009065 (2009).
59. Nemoto K, Hirota K, Murakami K, Taniguti K, Murata H, Viducic D, et al. Effect of Varidase (streptodornase) on biofilm formed by Pseudomonas aeruginosa. Chemotherapy 2003; 49: 121-5.
60. Nemoto K, Hirota K, Ono T, Murakami K, Murakami K, Nagao D, et al. Effect of Varidase (streptokinase) on biofilm formed by Staphylococcus aureus. Chemotherapy 2000; 46: 111-5.
61. Hatch RA, Schiller NL. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998; 42: 974-7.
62. Yasuda H, Ajiki Y, Koga T, Yokota T. Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob Agents Chemother 1994; 38: 138-41.
63. Shuford J, Steckelberg J, Patel R. Effects of fresh garlic extract on Candida albicans biofilms. Antimicrob Agents Chemother 2005; 49: 473.
64. Perez-Giraldo C, Cruz-Villalon G, Sanchez-Silos R, Martínez-Rubio R, Blanco MT, Gómez-García AC. In vitro activity of allicin against Staphylococcus epidermidis and influence of subinhibitory concentrations on biofilm formation. J Appl Microbiol 2003; 95: 709-11.
65. Dewhurst E, Rawson DM, Steele GC. The use of a model system to compare the efficiency of ultrasound and agitation in the recovery of Bacillus subtilis spores from polymer surfaces. J Appl Bacteriol 1986; 61: 357-63.
66. Carmen JC, Roeder BL, Nelson JL, Beckstead BL, Runyan CM, Schaalje GB, et al. Ultrasonically enhanced vancomycin activity against Staphylococcus epidermidis biofilms in vivo. J Biomater Appl 2004; 18: 237-45.
67. Rediske AM, Roeder BL, Nelson JL, Robison RL, Schaalje GB, Robison RA, et al. Pulsed ultrasound enhances the killing of Escherichia coli biofilms by aminoglycoside antibiotics in vivo. Antimicrob Agents Chemother 2000; 44: 771-2.
68. Rediske AM, Roeder BL, Brown MK, Nelson JL, Robison RL, Draper DO, et al. Ultrasonic enhancement of antibiotic action on Escherichia coli biofilms: An in vivo model. Antimicrob Agents Chemother 1999; 43: 1211-4.
69. Pitt WG, Ross SA. Ultrasound increases the rate of bacterial cell growth. Biotechnol Prog 2003; 19: 1038-44.
70. del Pozo JL, Rouse MS, Patel R. Bioelectric effect and bacterial biofilms. A systematic review. Int J Artif Organs 2008; 31: 786-95.
71. Rijnaarts HM, Norde W, Bouwer EJ, Lyklema J, Zehnder AJB. Bacterial adhesion under static and dynamic conditions. Appl Environ Microbiol 1993; 59: 3255-65.
72. Jucker BA, Harms H, Zehnder AJ. Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and Teflon. J Bacteriol 1996; 178: 5472-79.
73. van der Borden AJ, van der Mei HC, Busscher HJ. Electric block current induced detachment from surgical stainless steel and decreased viability of Staphylococcus epidermidis. Biomaterials 2005; 26: 6731-5.
74. Ueshima M, Tanaka S, Nakamura S, Yamashita K. Manipulation of bacterial adhesion and proliferation by surface charges of electrically polarized hydroxyapatite. J Biomed Mater Res 2002; 60: 578-84.
75. Poortinga AT, Bos R, Busscher HJ. Controlled electrophoretic deposition of bacteria to surfaces for the design of biofilms. Biotechnol Bioeng 2000; 67: 117-20.
76. Liu WK, Brown MR, Elliott TS. Mechanisms of the bactericidal activity of low amperage electric current (DC). J Antimicrob Chemother 1997; 39: 687-95.
77. Shimada K, Shimahara K. Leakage of cellular contents and morphological changes in resting Escherichia coli B cells exposed to an alternating changes. Agric Biol Chem 1985; 49: 3605-7.
78. Matsunaga T, Nakasono S, Masuda S. Electrochemical sterilization of bacteria absorbed on granular activated carbon. FEMS Microbiol Lett 1992; 72: 255-9.
79. del Pozo JL, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R. The electricidal effect: Reduction of Staphylococcus and Pseudomonas biofilms by prolonged exposure to low-intensity electrical current. Antimicrob Agents Chemother 2009; 53: 41-5.
80. del Pozo JL, Rouse MS, Euba G, Kang CI, Mandrekar JN, Steckelberg JM, et al. The electrical effect is active in an experimental model of Staphylococcus epidermidis chronic foreign body osteomyelitis. Antimicrob Agents Chemother 2009; 53: 4064-8.
81. Raad I, Hachem R, Zermeno A, Stephens LC, Bodey GP. Silver iontophoretic catheter: A prototype of a long-term antiinfective vascular access device. J Infect Dis 1996; 173: 495-8.
82. Costerton JW, Ellis B, Lam K, Johnson F, Khoury AE. Mechanism of electrical enhancement of efficacy of antibiotics in killing biofilm bacteria. Antimicrob Agents Chemother 1994; 38: 2803-9.
83. Stewart PS, Wattanakaroon W, Goodrum L, Fortun SM, McLeod BR. Electrolytic generation of oxygen partially explains electrical enhancement of tobramycin efficacy against Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother 1999; 43: 292-6.
84. Pickering SAW, Bayston R, Scanlin TF. Electromagnetic augmentation of antibiotic efficacy in infection of orthopaedic implants. J Bone Jt Surg BR 2003; 85B: 588-93.
85. del Pozo JL, Rouse MS, Mandrekar JN, Sampedro MF, Steckelberg JM, Patel R. Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 2009; 53: 35-40.
86. Sersa G, Miclavcic D. Inhibition of SA-1 tumor growth in mice by human leukocyte interferon alpha combined with low-level direct current. Mol Biother 1990; 2: 165-8.
87. Belehradek JJr, Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electropermeabilization of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. Biochim Biophys Acta 1994; 1190: 155-63.
88. Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 2009; 17: 66-72.
89. Rohwer F. Global phage diversity. Cell 2003; 113: 141.
90. Richards JJ, Melander C. Controlling bacterial biofilms. Chembiochem 2009; 10: 2287-94.
91. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649-59.
92. Deresinski S. Bacteriophage therapy: Smaller fleas. Clin Infect Dis 2009; 48: 1096-101.
93. Kimura K, Itoh Y. Characterization of poly-gamma-glutamate hydrolase encoded by a bacteriophage genome: Possible role in phage infection of Bacillus subtilis encapsulated with poly-gamma-glutamate. Appl Environ Microbiol 2003; 69: 2491-7.
94. Sutherland IW. Phage-induced fucosidases hydrolysing the exopolysaccharide of Klebsiella aerogenes type 54 [A3(S1)]. Biochem J 1967; 104: 278-85.
95. Adams MH, Park BH. An enzyme produced by a phage-host cell system. II. The properties of the polysaccharide depolymerase. Virology 1956; 2: 719-36.
96. Doolittle MM, Cooney JJ, Caldwell DE. Lytic infection of Escherichia coli biofilms by bacteriophage T4. Can J Microbiol 1995; 41: 12-8.
97. Doolittle MM, Cooney JJ, Caldwell DE. Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J Ind Microbiol 1996; 16: 331-41.
98. Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 2001; 67: 2746-53.
99. Deveau H, Van Calsteren MR, Moineau S. Effect of exopolysaccharides on phage-host interactions in Lactococcus lactis. Appl Environ Microbiol 2002; 68: 4364-9.
100. Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 2007; 104: 11197-202.
101. Itoh Y, Wang X, Hinnebusch BJ, Preston JF, Romeo T. Depolymerization of beta-1,6-N-acetyl-D-glucosamine disrupts the integrity of diverse bacterial biofilms. J Bacteriol 2005; 187: 382-7.
102. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002; 295: 1487-1487.
103. Johansen C, Falholt P, Gram L. Enzymatic removal and disinfection of bacterial biofilms. Appl Environ Microbiol 1997; 63: 3724-8.
104. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA 2009; 106: 4629-34.
105. Collins, J.J., Lu, T.K. Engineered bacteriophages as adjuvants for antimicrobial agents and compositions and methods of use thereof. WO2009108406 (2009).
106. Curtin JJ, Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 2006; 50: 1268-75.
107. Azeredo J, Sutherland, IW. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 2008; 9: 261-6.
108. Jerne NK, Avegno P. The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: Reversible and irreversible inactivation. J Immunol 1956; 76: 200-8.
109. Sutherland IW, Hughes KA, Skillman LC, Tait K. The interaction of phage and biofilms. FEMS Microbiol Lett 2004; 232: 1-6.
110. Sillankorva S, Oliviera R, Vieira MJ, Sutherland IW, Azeredo J. Bacteriophage Phi S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 2004; 20: 133-8.
111. Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: The role of phage-borne polysaccharide depolymerase. Microbiol 1998; 144: 3039-47.
112. Sharp, R., Hughes, G., Hart, A., Walker, J.T. Bacteriophage for the treatment of bacterial biofilms. WO2004062677 (2004).
113. Fuqua WC, Winans SC, Greenberg EP. Quorum sensing in bacteria: The LuxR-LuxI family of cell density-responsive transcriptional regulators. J Bacteriol 1994; 176: 269-75.
114. Engebrecht J, Silverman M. Identification of genes and gene products necessary for bacterial bioluminescence. Proc Natl Acad Sci USA 1984; 81: 4154-8.
115. Eberl L. N-acyl homoserinelactone-mediated gene regulation in gram-negative bacteria. Syst Appl Microbiol 1999; 22: 493-506.
116. Parsek MR, Val DL, Hanzelka BL, Cronan JE, Greenberg EP. Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci USA 1999; 96: 4360-5.
117. Salmond GP, Bycroft BW, Stewart GS, Williams P. The bacterial 'enigma': Cracking the code of cell-cell communication. Mol Microbiol 1995; 16: 615-24.
118. Schuster M, Urbanowski ML, Greenberg EP. Promoter specificity in Pseudomonas aeruginosa quorum sensing revealed by DNA binding of purified LasR. Proc Natl Acad Sci USA 2004; 101: 15833-9.
119. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003; 22: 3803-15.
120. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: Effects of growth phase and environment. J Bacteriol 2003; 185: 2080-95.
121. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as antipathogenic drugs. Int J Med Microbiol 2006; 296: 149-61.
122. Rasmussen TB, Givskov M. Quorum sensing inhibitors: A bargain of effects. Microbiol 2006; 152: 895-904.
123. Yates EA, Philipp B, Buckley C, Atkinson S, Chhabra SR, Sockett RE, et al. N-Acylhomoserinelactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect Immun 2002; 70: 5635-46.
124. Byers JT, Lucas C, Salmond GP, Welch M. Nonenzymatic turnover of an Erwinia carotovora quorum-sensing signaling molecule. J Bacteriol 2002; 184: 1163-71.
125. Wang LH, Weng LX, Dong YH, Zhang LH. Specificity and enzyme kinetics of the quorum-quenching N-acyl homoserine lactone lactonase (AHL-lactonase). J Biol Chem 2004; 279: 13645-51.
126. Lee SJ, Park SY, Lee JJ, Yum DY, Koo BT, Lee JK. Genes encoding the N-acyl homoserine lactone-degrading enzyme are widespread in many subspecies of Bacillus thuringiensis. Appl Environ Microbiol 2002; 68: 3919-24.
127. Dong YH, Wang LH, Xu JL, Zhang HB, Zhang XF, Zhang LH. Quenching quorum-sensing-dependent bacterial infection by an Nacyl homoserine lactonase. Nature 2001; 411: 813-7.
128. Dong YH, Xu JL, Li XZ, Zhang LH. AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. Proc Natl Acad Sci USA 2000; 97: 3526-31.
129. Dong YH, Zhang XF, Xu JL, Zhang LH. Insecticidal Bacillus thuringiensis silences Erwinia carotovora virulence by a new form of microbial antagonism, signal interference. Appl Environ Microbiol 2004; 70: 954-60.
130. Molina L, Constantinescu F, Michel L, Reimmann C, Duffy B, Defago G. Degradation of pathogen quorum-sensing molecules by soil bacteria: A preventive and curative biological control mechanism. FEMS Microbiol Ecol 2003; 45: 71-81.
131. Uroz S, D'Angelo-Picard C, Carlier A, Elasri M, Sicot C, Petit A, et al. Novel bacteria degrading N-acylhomoserine lactones and their use as quenchers of quorum-sensing-regulated functions of plant-pathogenic bacteria. Microbiology 2003; 149: 1981-9.
132. Carlier A, Uroz S, Smadja B, Fray R, Latour X, Dessaux Y, et al. The Ti plasmid of Agrobacterium tumefaciens harbors an attMparalogous gene, aiiB, also encoding N-acyl homoserine lactonase activity. Appl Environ Microbiol 2003; 69: 4989-93.
133. Park SY, Lee SJ, Oh TK, Oh JW, Koo BT, Yum DY, et al. AhlD, an N-acylhomoserine lactonase in Arthrobacter sp. and predicted homologues in other bacteria. Microbiology 2003; 149: 1541-50.
134. Huang JJ, Han JI, Zhang LH, Leadbetter JR. Utilization of acylhomoserine lactone quorum signals for growth by a soil pseudomonad and Pseudomonas aeruginosa PAO1. Appl Environ Microbiol 2003; 69: 5941-9.
135. Camara M, Williams P, Hardman A. Controlling infection by tuning in and turning down the volume of bacterial small-talk. Lancet Infect Dis 2002; 2: 667-76.
136. Borchardt SA, Allain EJ, Michels JJ, Stearns GW, Kelly RF, McCoy WF. Reaction of acylated homoserine lactone bacterial signaling molecules with oxidized halogen antimicrobials. Appl Environ Microbiol 2001; 67: 3174-9.
137. Leadbetter JR, Greenberg EP. Metabolism of acylhomoserine lactone quorum-sensing signals by Variovorax paradoxus. J Bacteriol 2000; 182: 6921-6.
138. Chun CK, Ozer EA, Welsh MJ, Zabner J, Greenberg EP. Inactivation of a Pseudomonas aeruginosa quorum-sensing signal by human airway epithelia. Proc Natl Acad Sci USA 2004; 101: 3587-90.
139. Hastings JW. Bacterial quorum-sensing signals are inactivated by mammalian cells. Proc Natl Acad Sci USA 2004; 101: 3993-4.
140. Steinberg PD, Schneider R, Kjelleberg S. Chemical defenses of seaweeds against microbial colonization. Biodegradation 1997; 8: 211-20.
141. Maximilien R, de Nys R, Holmstrom C, Gram L, Givskov M, Kjelleberg S, et al. Chemical mediation of bacterial surface colonisation by secondary metabolites from the red alga Delisea pulchra. Aquat Microb Ecol 1998; 15: 233-46.
142. Rasmussen TB, Manefield M, Andersen JB, Eberl L, Anthoni U, Christophersen C, et al. How Delisea pulchra furanones affect quorum sensing and swarming motility in Serratia liquefaciens MG1. Microbiology 2000; 146: 3237-44.
143. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR, et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002; 148: 87-102.
144. Manefield M, Harris L, Rice SA, de Nys R, Kjelleberg S. Inhibition of luminescence and virulence in the black tiger prawn (Penaeus monodon) pathogen Vibrio harveyi by intercellular signal antagonists. Appl Environ Microbiol 2000; 66: 2079-84.
145. Ren D, Bedzyk LA, Setlow P, England DF, Kjelleberg S, Thomas SM, et al. Differential gene expression to investigate the effect of (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone on Bacillus subtilis. Appl Environ Microbiol 2004; 70: 4941-9.
146. Ren D, Sims JJ, Wood TK. Inhibition of biofilm formation and swarming of Bacillus subtilis by (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone. Lett Appl Microbiol 2002; 34: 293-9.
147. Wang, B., Ni, N., Wang, J., Lu, C.D., Chou, H.T., Li, M., Zheng, S., Cheng, Y., Peng, H. Compositions for regulating or modulating quorum sensing in bacteria, methods of using the compounds, and methods of regulating or modulating quorum sensing in bacteria. WO2009029317 (2009).
148. Mathee, K., Adonizio, A.L., Ausubel, F., Clardy, J., Bennett, B., Downum, K. Use of ellagitannins as inhibitors of bacterial quorum sensing. WO2009114810 (2009).
149. Janda, K.D., Kaufmann, G.F., Park, J. Antibody-mediated disruption of quorum sensing in bacteria. WO2009055054 (2009).
150. Rasmussen TB, Skindersoe ME, Bjarnsholt T, Christensen KB, Andersen JB, Ostenfeld-Larsen T, et al. Idendity and effects of quorum sensing inhibitors produced by Penicillum species. Microbiology 2005; 151: 1325-40.
151. Balaban N, Giacometti A, Cirioni O, Gov Y, Ghiselli R, Mocchegiani F, et al. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis 2003; 187: 625-30.
152. Balaban N, Gov Y, Bitler A, Boelaert JR. Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells. Kidney Int 2003; 63: 340-5.
153. Balaban N, Stoodley P, Fux CA, Wilson S, Costerton JW, Dell'Acqua G. Prevention of staphylococcal biofilm-associated infections by the quorum sensing inhibitor RIP. Clin Orthop Relat Res 2005; 437: 48-54.
154. Rosenberg LE, Carbone AL, Römling U, Uhrich KE, Chikindas ML. Salicylic acid-based poly(anhydride esters) for control of biofilm formation in Salmonella enterica serovar Typhimurium, Lett. Appl Microbiol 2008; 46: 593-9.
155. Bryers JD, Jarvis RA, Lebo J, Prudencio A, Kyriakides TR, Uhrich, K. Biodegradation of poly(anhydride-esters) into non-steroidal anti-inflammatory drugs and their effect on Pseudomonas aeruginosa biofilms in vitro and on the foreign-body response in vivo. Biomaterials 2006; 27: 5039-48.
156. Brackman G, Defoirdt T, Miyamoto C, Bossier P, Van Calenbergh S, Nelis H, et al. Cinnamaldehyde and cinnamaldehyde derivatives reduce virulence in Vibrio sp. by decreasing the DNA-binding activity of the quorum sensing response regulator LuxR. BMC Microbiol 2008; 8: 149.
157. Bjarnsholt T, Jensen PO, Rasmussen TB, Christophersen L, Calum H, Hentzer M, et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology 2005; 151 (Part 12): 3873-80.
158. Duarte S, Gregoire S, Singh AP, Vorsa N, Schaich K, Bowen WH, et al. Inhibitory effects of cranberry polyphenols on formation and acidogenicity of Streptococcus mutans biofilms. FEMS Microbiol Lett 2006; 257: 50-6.
159. Labrecque J, Bodet C, Chandad F, Grenier D. Effects of a high-molecular-weight cranberry fraction on growth, biofilm formation and adherence of Porphyromonas gingivalis. J Antimicrob Chemother 2006; 58: 439-43.
160. Yamanaka A, Kouchi T, Kasai K, Kato T, Ishihara K, Okuda K. Inhibitory effect of cranberry polyphenol on biofilm formation and cysteine proteases of Porphyromonas gingivalis. J Periodontal Res 2007; 42: 589-92.
161. Yamanaka A, Kimizuka R, Kato T, Okuda K. Inhibitory effects of cranberry juice on attachment of oral streptococci and biofilm formation. Oral Microbiol Immunol 2004; 19: 150-4.
162. Rasmussen TB, Bjarnsholt T, Skindersoe ME, Hentzer M, Kristoffersen P, Kote M, et al. Screening for quorum sensing inhibitors using a novel genetic system-the QSI selector. J Bacteriol 2005; 187: 1799-814.
163. Teplitski M, Robinson JB, Bauer WD. Plants secrete substances that mimic bacterial N-acyl homoserine lactone signal activities and affect population density-dependent behaviors in associated bacteria. Mol Plant Microbe Interact 2000; 13: 637-48.
164. Persson T, Hansen TH, Rasmussen TB, Skinderso ME, Givskov M, Nielsen J. Rational design and synthesis of new quorum-sensing inhibitors derived from acylated homoserine lactones and natural products from garlic. Org Biomol Chem 2005; 3: 253-62.
165. Rice SA, McDougald D, Kumar N, Kjelleberg S. The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections. Curr Opin Investig Drugs 2005; 6: 178-84.
166. Jabra-Rizk MA, Meiller TF, James CE, Shirtliff ME. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 2006; 50: 1463-9.
167. Ren D, Zuo R, Gonzalez Barrios AF, Bedzyk LA, Eldridge GR, Pasmore ME, et al. Differential gene expression for investigation of Escherichia coli biofilm inhibition by plant extract ursolic acid. Appl Environ Microbiol 2005; 71: 4022-34.
168. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62S-69S, quiz 69S.
169. Chen X, Stewart PS. Biofilm removal caused by chemical treatments. Water Res 2000; 34: 4229-33.
170. Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002; 184: 1140-54.
171. Thormann KM, Saville RM, Shukla S, Spormann AM. Induction of rapid detachment in Shewanella oneidensis MR-1 biofilms. J Bacteriol 2005; 187: 1014-21.
172. Gjermansen M, Ragas P, Sternberg C, Molin S, Tolker-Nielsen T. Characterization of starvation-induced dispersion in Pseudomonas putida biofilms. Environ Microbiol 2005; 7: 894-993.
173. Webb JS, Thompson LS, James S, Charlton T, Tolker-Nielsen T, Koch B, et al. Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol 2003; 185: 4585-92.
174. Barraud N, Hassett DJ, Hwang S-H, Rice SA, Kjelleberg S, Webb JS. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006; 188: 7344-53.
175. Banin E, Brady KM, Greenberg EP. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl Environ Microbiol 2006; 72: 2064-9.
176. Lee J, Jayaraman A, Wood TK. Indole is an inter-species biofilm signal mediated by SdiA. BMC Microbiol 2007; 7 (42): 1-15.
177. Lee J, Bansal T, Jayaraman A, Bentley WE, Wood TK. Enterohemorrhagic Escherichia coli biofilms are inhibited by 7-hydrozyindole and stimulated by isatin. Appl Environ Microbiol 2007b; 73: 4100-9.
178. Rice SA, Koh KS, Queck SY, Labbate M, Lam KW, Kjelleberg S. Biofilm formation and sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. J Bacteriol 2005; 187: 3477-85.
179. Dow JM, Crossman L, Findlay K, He Y.-Q, Feng J.,-X, Tang J.-L. Biofilm dispersal in Xanthomonas campestris is controlled by cell-cell signaling and is required for full virulence to plants. Proc Natl Acad Sci USA 2003; 100: 10995-11000.
180. Davies DG, Marques CN. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J Bacteriol 2009; 191: 1393-403.
181. Tanihara M, Suzuki Y, Nishimura Y, Suzuki K, Kakimaru Y, Fukunisi, Y. A novel microbial infection-responsive drug release system. J Pharm Sci 1999; 88: 510-4.
182. Geddes A. Infection in the twenty-first century: Predictions and postulates. J Antimicrob Chemother 2000; 46: 873-8.
183. Beaudoin D, Bryers JD, Cunningham AB, Peretti SW. Mobilization of broad host range plasmid from Pseudomonas putida to established biofilm of Bacillus azotoformans. I, Experiments. Biotechnol Bioeng 1998; 57: 272-9.
184. Beaudoin D, Bryers JD, Cunningham AB, Peretti SW. Mobilization of broad host range plasmid from Pseudomonas putida to established biofilm of Bacillus azotoformans. II, Modeling. Biotechnol Bioeng 1998b; 57: 280-6.
185. Fischetti VA. Bacteriophage lytic enzymes: Novel anti-infectives. Trends Microbiol 2005; 13: 491-6.
186. Hong HA, Ducle H, Cutting SM. The use of bacterial spore formers as probiotics. FEMS Microbiol Rev 2005; 29: 813-35.
187. Persson GR. Immune responses and vaccination against periodontal infections. J Clin Periodontol 2005; 32 (Suppl 6): 39-53.
188. De Smet K, Contreras R. Human antimicrobial peptides: Defensins, cathelicidins and histatins. Biotechnol Lett 2005; 27: 1337-47.
189. Bryers JD. Medical biofilms. Biotechnol Bioeng 2008; 100: 1-18.
190. Barclay R, Ratledge C. Participation of iron on the growth inhibition of pathogenic strains of Mycobacterium avium and M. paratuberculosis in serum. Zentralbl Bakteriol Mikrobiol Hyg [A] 1986; 262: 189-94.
191. Ankenbauer R, Sriyosachati S, Cox CD. Effects of siderophores on the growth of Pseudomonas aeruginosa in human serum and transferrin. Infect Immun 1985; 49: 132-40.
192. Finkelstein RA, Sciortino CV, McIntosh MA. Role of iron in microbe-host interactions. Rev Infect Dis 1983; 5 (Suppl 4): S759-S777.
193. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997; 25: 888-95.
194. Singh PK. Iron sequestration by human lactoferrin stimulates P. aeruginosa surface motility and blocks biofilm formation. Biometals 2004; 17: 267-70.
195. Narasimhan J, Antholine WE, Chitambar CR. Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochem Pharmacol 1992; 44: 2403-8.
196. Chitambar CR, Narasimhan J. Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology 1991; 59: 3-10.
197. Atkinson RA, Salah El, Din AL, Kieffer B, Lefevre JF, Abdallah MA. Bacterial iron transport: 1H NMR determination of the three-dimensional structure of the gallium complex of pyoverdin G4R, the peptidic siderophore of Pseudomonas putida G4R. Biochemistry 1998; 37: 15965-73.
198. Hubbard JA, Lewandowska KB, Hughes MN, Poole RK. Effects of iron-limitation of Escherichia coli on growth, the respiratory chains and gallium uptake. Arch Microbiol 1986; 146: 80-6.
199. Krishnamurthy VM, Quinton LJ, Estroffa LA, Metaletal SJ, Issacs JM, Mizgerd JP, et al. Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide. Biomaterials 2006; 27: 3663-74.
200. Kuhn SE, Nardin A, Klebba PE, Taylor RP. Escherichia coli bound to the primate erythrocyte complement receptor via bispecific monoclonal antibodies are transferred to and phagocytosed by human monocytes in an in vitro model. J Immunol 1998; 160: 5088-97.
201. Lindorfer MA, Nardin A, Foley PL, Solga MD, Bankovich AJ, Martin EN, et al. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J Immunol 2001; 167: 2240-9.
202. Gyimesi E, Bankovich AJ, Schuman TA, Goldberg JB, Lindorfer MA, Taylor RP. Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol Lett 2004; 95: 185-92.
203. Kobayashi T, Takauchi A, van Spriel AB, Vilé HA, Hayakawaf M, Abiko Y, et al. Targeting of Porphyromonas gingivalis with a bispecific antibody directed to Fc RI (CD89) improves in vitro clearance by gingival crevicular neutrophils. Vaccine 2004; 23: 585-94.
204. Wizemann TM, Adamou JE, Langermann S. Adhesins as targets for vaccine development. Emerg Infect Dis 1999; 5: 395-403.
205. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immuno-suppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10: 187-92.
206. Zhao H, Hemmi H, Akira S, Cheng SH, Scheule RK, Yew NS. Contribution of Toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol Ther 2004; 9: 241-8.
207. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA transfected dendritic cells. Immunol Rev 2004; 199: 251-63.
208. Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev 2006; 58: 487-99.
209. Gao Y, Gu W, Chen L, Xu Z, Li Y. A multifunctional nanodevice as non-viral vector for gene delivery: In vitro characteristics and transfection. J Control Release 2007; 118: 381-388.
210. Keegan ME, Saltzman WM. Surface-modified biodegradable microspheres for DNA vaccine delivery. Methods Mol Med 2006; 127: 107-13.
211. Little SR, Langer R. Nonviral delivery of cancer genetic vaccines. Adv Biochem Eng Biotechnol 2005; 99: 93-118.
212. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov 2005; 4: 581-93.
213. Varshavsky A, Turner G, Du F, Xie Y. Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway. Biol Chem 2000; 381: 779-89.
214. Tobery T, Siliciano RF. Cutting edge: Induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen. J Immunol 1999; 162: 639-42.
215. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997; 185: 909-20.
216. Bonini C, Lee SP, Riddell SR, Greenberg PD. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J Immunol 2001; 166: 5250-7.
217. Thomson SA, Burrows SR, Misko IS, Moss DJ, Coupar BE, Khanna R. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: A novel approach to vaccine design. J Virol 1998; 72: 2246-52.
218. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-6.
219. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995; 92: 11671-5.
220. Bennewitz NL, Babensee JL. The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen. Biomaterials 2005; 26: 2991-9.
221. DiTizio V, Ferguson GW, Mittelman MW, Khoury AE, Bruce AW, DiCosmo F. A liposomal hydrogel for the prevention of bacterial adhesion to catheters. Biomaterials 1998; 19: 1877-84.
222. Finelli A, Burrows LL, DiCosmo FA, DiTizio V, Sinnadurai S, Oreopoulos DG, et al. Colonization-resistant antimicrobial-coated peritoneal dialysis catheters: evaluation in a newly developed rat model of persistent Pseudomonas aeruginosa peritonitis. Perit Dial Int 2002; 22: 27-31.
223. Pugach JL, DiTizio V, Mittelman MW, Bruce AW, DiCosmo F, Khoury AE. Antibiotic hydrogel coated Foley catheters for prevention of urinary tract infection in a rabbit model. J Urol 1999; 162: 883-7.
224. Ahmed K, Gribbon PN, Jones MN. The application of confocal microscopy to the study of liposome adsorption onto bacterial biofilms. J Liposome Res 2002; 12: 285-300.
225. Catuogno C, Jones MN. The antibacterial properties of solid supported liposomes on Streptococcus oralis biofilms. Int J Pharm 2003; 257: 125-40.
226. Bakker-Woudenberg IAJM, ten Kate MT, Guo L, Working P, Mouton JW. Ciprofloxacin in polyethylene glycol-coated liposomes: Efficacy in rat models of acute or chronic Pseudomonas aeruginosa Infection. Antimicrob Agents Chemother 2002; 46: 2575-81.
227. Ambiosome fact sheet, http://www.astellas.us/docs/ambisome.pdf accessed on 11-01-2010.
228. Zilberman M, Elsner JJ. Antibiotic-eluting medical devices for various applications. J Control Release 2008; 130: 202-15.
229. Buchholz HW, Engelbrecht H. Uber die Depotwirkung einiger Antibiotica bei Vermischung mit dem Kunstharz Palacos [Depot effects of various antibiotics mixed with Palacos resins]. Chirurg 1970; 41: 511-5.
230. Wahlig H, Buchholz HW. Experimental and clinical studies on the release of gentamicin from bone cement. Chirurg 1972; 43: 441-5.
231. Buchholz HW, Gartmann HD. Infection prevention and surgical management of deep insidious infection in total endoprothesis. Chirurg 1972; 43: 446-53.
232. Hanssen AD. Prophylactic use of antibiotic bone cement: an emerging standard-in opposition [comment]. J Arthroplast 2004; 19 (4 Suppl 1): 73-7.
233. Li LC, Deng J, Stephens D. Polyanhydride implant for antibiotic delivery-from the bench to the clinic. Adv Drug Deliv Rev 2002; 54: 963-86.
234. Krasko MY, Golenser J, Nyska A, Nyska M, Brin YS, Domb AJ. Gentamicin extended release from an injectable polymeric implant. J Control Rel 2007; 117: 90-6.
235. Chai F, Hornez JC, Blanchemain N, Neut C, Descamps M, Hildebrand HF. Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics. Biomol Eng 2007; 24: 510-4.
236. Alt V, Bitschnau A, Osterling J, Sewing A, Meyer C, Kraus R, et al. The effects of combined gentamicin-hydroxyapatite coating for cementless joint prostheses on the reduction of infection rates in a rabbit infection prophylaxis model. Biomaterials 2006; 27: 4627-34.
237. Raschke MJ, Schmidmaier G. [Biological coating of implants in trauma and orthopedic surgery]. Unfallchirurg 2004; 107: 653-663.
238. Schmidmaier G, Lucke M, Wildemann B, Haas NP, Raschke M. Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury 2006; 37 (Suppl 2): S105-S112.
239. Gürsel I, Korkusuz F, Türesin F, Alaeddinoglu NG, Hasirci V. In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Biomaterials 2001; 22: 73-80.
240. Aviv M, Berdicevsky I, Zilberman M. Gentamicin-loaded bioresorbable films for prevention of bacterial infections associated with orthopedic implants. J Biomed Mater Res A 2007; 83: 10-9.
241. Zilberman M, Shifrovitch Y, Aviv M, Hershkovitz M. Structured drug-eluting bioresorbable films: Microstructure and release profile. J Biomater Appl 2009; 23: 385-406.
242. Zilberman M, Malka A. Drug controlled release from structured bioresorbable films used in medical devices-a mathematical model. J Biomed Mater Res B Appl Biomater 2009; 89: 155-64.
243. Koort JK, Suokas E, Veiranto M, Mäkinen TJ, Jalava J, Törmälä P, et al. In vitro and in vivo testing of bioabsorbable antibiotic containing bone filler for osteomyelitis treatment. J Biomed Mater Res 2006; 78A: 532-40.
244. Lee SH, Lee JE, Baek WY, Lim JO. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistance Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J Control Rel 2004; 96: 1-7.
245. Tebbs SE, Sawyer A, Elliott TS. Influence of surface morphology on in vitro bacterial adherence to central venous catheters. Br J Anaesth 1994; 72: 587-91.
246. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonization of catheters. Antimicrob Agents Chemother 1995; 39: 2397-400.
247. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996; 173: 418-24.
248. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: A randomized, double-blind trial, The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127: 267-74.
249. Johnson JR, Delavari P, Azar M. Activities of a nitrofurazone containing urinary catheter and a silver hydrogel catheter against multidrug resistant bacteria characteristic of catheter-associated urinary tract infection. Antimicrob Agents Chemother 1999; 43: 2990-5.
250. Quesnel LB, Al Najjar AR, Buddhavudhikrai P. Synergism between chlorhexidine and sulphadiazine. J Appl Bacteriol 1978; 45: 397-405.
251. Brun-Buisson C, Doyon F, Sollet JP, Cochard JF, Cohen Y, Nitenberg G. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver-sulfadiazine-catheters. Intensive Care Med 2004; 30: 837-43.
252. Richardson RL Jr, Pate JW, Wolf RY, Ledes C, Hopson WB Jr. The outcome of antibiotic-soaked arterial grafts in guinea pig wounds contaminated with E. coli or S. aureus. J Thorac Cardiovasc Surg 1970; 59: 635-7.
253. Galdbart JO, Branger C, Andreassian B, Lambert-Zechovsky N, Kitzis, M. Elution of six antibiotics bonded to polyethylene vascular grafts sealed with three proteins. J Surg Res 1996; 66: 174-8.
254. Blanchemain N, Haulon S, Boschin F, Traisnel M, Morcellet M, Martel B, et al. Vascular prostheses with controlled release of antibiotics Part 2. in vitro Biological evaluation of vascular prostheses treated by cyclodextrins. Biomol Eng 2007; 24: 143-8.
255. Böswald M, Lugauer S, Regenfus A, Braun GG, Martus P, Geis C, et al. Reduced rates of catheter-associated infection by use of a new silver-impregnated central venous catheter. Infection 1999; 27 (Suppl1): S56-S60.
256. Stoiser B, Kofler J, Staudinger T, Georgopoulos A, Lugauer S, Guggenbichler JP, et al. Contamination of central venous catheters in immunocompromised patients; a comparison between two different types of central venous catheters. J Hosp Infect 2002; 50: 202-6.
257. Lellouche J, Kahana E, Elias S, Gedanken A, Banin E. Antibiofilm activity of nanosized magnesium fluoride. Biomaterials 2009; 30: 5969-78.